We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-5.92%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.83B
AUM Growth
-$114M
Cap. Flow
+$174M
Cap. Flow %
6.13%
Top 10 Hldgs %
45.99%
Holding
98
New
13
Increased
2
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
BMEA icon
Biomea Fusion
BMEA
+$36.9M
2
DAWN
Day One Biopharmaceuticals
DAWN
+$24.8M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$21.3M
4
GHRS icon
GH Research
GHRS
+$20.7M
5
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$20.6M

Top Sells

Rank Stock Value
1
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$27.2M
2
ARYD
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
+$10.3M
3
VINCU
Vincerx Pharma, Inc. Unit
VINCU
+$8.1M
4
ACHL
Achilles Therapeutics
ACHL
+$2.6K

Sector Composition

Rank Sector Weight
1 Healthcare 97.6%
2 Financials 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELEV
51
DELISTED
Elevation Oncology
ELEV
$18.2M 0.64%
+1,341,530
New +$16.6M
CBAY
52
DELISTED
Cymabay Therapeutics
CBAY
$17.4M 0.62%
4,000,000
– –
TLIS
53
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$17.1M 0.6%
103,400
– –
XENE icon
54
Xenon Pharmaceuticals
XENE
$6.06B
$16M 0.56%
+857,000
New +$15.8M
SLDB icon
55
Solid Biosciences
SLDB
$794M
$15.5M 0.55%
282,305
– –
FSTX
56
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$15M 0.53%
+1,751,428
New +$14.9M
ACHL
57
DELISTED
Achilles Therapeutics
ACHL
$15M 0.53%
1,536,016
-192
-0% -$2.6K
MIST icon
58
Milestone Pharmaceuticals
MIST
$138M
$14.1M 0.5%
2,572,194
– –
NGNE icon
59
Neurogene
NGNE
$656M
$13.9M 0.49%
75,053
– –
CABA icon
60
Cabaletta Bio
CABA
$437M
$13.8M 0.49%
1,603,361
– –
RNAC icon
61
Cartesian Therapeutics
RNAC
$229M
$13.7M 0.48%
109,469
– –
PSTX
62
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$12.5M 0.44%
1,251,055
– –
ESPR
63
DELISTED
Esperion Therapeutics
ESPR
$10.6M 0.37%
500,000
– –
IMVT icon
64
Immunovant
IMVT
$7.93B
$10.6M 0.37%
1,000,000
– –
NGM
65
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$9.86M 0.35%
+500,000
New +$11.7M
IMMP
66
Immutep
IMMP
$56.3M
$9.68M 0.34%
2,500,000
+500,000
+25% +$1.98M
BLU
67
DELISTED
BELLUS Health Inc.
BLU
$9.25M 0.33%
2,975,000
– –
MTNB icon
68
Matinas BioPharma
MTNB
$1.88M
$8.89M 0.31%
229,573
– –
IRON icon
69
Disc Medicine
IRON
$2.96B
$8.41M 0.3%
43,333
– –
LITS
70
Lite Strategy Inc
LITS
$32.8M
$8.3M 0.29%
145,655
– –
QURE icon
71
uniQure
QURE
$3.03B
$7.7M 0.27%
250,000
– –
NAUT icon
72
Nautilus Biotechnolgy
NAUT
$124M
$7.58M 0.27%
+750,000
New +$8.12M
VINC
73
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$5.85M 0.21%
+22,500
New +$6.85M
ASMB icon
74
Assembly Biosciences
ASMB
$498M
$5.82M 0.21%
125,000
– –
MIRM icon
75
Mirum Pharmaceuticals
MIRM
$6.46B
$5.48M 0.19%
317,000
– –
1 2
3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Boxer Capital held 98 positions worth $2.83B, down 3.9% from $2.95B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Boxer Capital deployed $174M of net new capital in Q2 2021, opening 13 new positions and adding to 2 existing holdings. Its largest new stake was Biomea Fusion: 2,088,405 shares worth $32.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Achilles Therapeutics, an estimated $2.6K trimmed.

  • Boxer Capital's largest Q2 2021 buy was Biomea Fusion: 2,088,405 shares worth $32.6M.
  • Boxer Capital added most to POINT Biopharma Global Inc. Common Stock in Q2 2021, an estimated $10.2M increase.
  • Boxer Capital's biggest Q2 2021 reduction was Achilles Therapeutics, cutting an estimated $2.6K.
  • Boxer Capital fully exited Direxion Daily S&P Biotech Bear 3X ETF in Q2 2021, selling an estimated $27.2M.
  • Boxer Capital's ten largest holdings make up 46% of its $2.83B portfolio in Q2 2021.
  • Boxer Capital opened 13 new positions and closed 3 in Q2 2021.
  • Boxer Capital's portfolio value fell 3.9% quarter-over-quarter to $2.83B.

Based on Boxer Capital's 13F filing for Q2 2021, filed 16 Aug 2021.